We assessed the outcome of 170 patients with AML in first complete remission, aged 1-47 years (median 29), who had undergone an allogeneic BMT before or after 1990 (n ¼ 80 and n ¼ 90, respectively); all patients were prepared with cyclophosphamide and TBI; the median follow-up for surviving patients was 13 years. The donor was an HLA-identical sibling in 164 patients. Transplantrelated mortality (TRM) was 30% before and 7% after 1990 (Po0.001); relapse-related death (RRD) was 26 and 11% (P ¼ 0.002); and actuarial 10-year survival was 42 and 79% (Po0.00001). Patients transplanted after 1990 were older, had a shorter interval diagnosis-BMT, had less FAB-M3 cases, received a higher dose of TBI, a higher marrow cell dose and combined (cyclosporine þ methotrexate) GVHD prophylaxis. Patients relapsing after transplant had an actuarial survival of 0 vs 31% if grafted before or after 1990 (P ¼ 0.01), and their median follow-up exceeds 10 years. In conclusion, the overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two decades, despite older age and fewer M3 cases. Improvement has come not only from changes in transplant procedures, but also from effective rescue of patients relapsing after transplant.
Introduction
Treatment strategies for patients with AML in 1st CR have been a matter of debate over the past two decades. Randomized studies have been conducted to assess whether chemotherapy (CT), or autologous transplants or allogeneic transplants would produce a different outcome in 1st CR AML. [1] [2] [3] [4] These studies show that allogeneic transplantation protects patients against leukemia relapse: however, the advantage is offset by increased transplant-related mortality (TRM), such that survival is improved in some, but not in all studies. [5] [6] [7] [8] In the EORTC/GIMEMA trial, disease-free survival (DFS) at 4 years was reported to be 55, 48 and 30% for patients receiving post-remission allogeneic BMT, autologous BMT or CT, respectively. 1 The AML-10 Medical Research Council trial showed a DFS of 50 versus 42% on a donor versus no-donor basis. 5 The issue is complicated by the heterogeneity of AML, based on the French-American-British (FAB) subtype, cytogenetics, number of courses of CT to achieve remission, and Flt3 mutations and results of transplantation may differ in patients with different risk factors. [9] [10] [11] [12] [13] A recent metanalysis of five randomized studies found a significant survival advantage for transplantation in the poor-risk AML, no advantage in favorable-risk AML and a non-significant advantage in patients with intermediate risk. 8 The need to diminish TRM has prompted many investigators to use nonmyeloablative or reduced intensity conditioning (RIC) regimens: a recent report suggests that RIC regimens in 1st CR AML reduce TRM, but at the expense of increased relapse, and survival is not improved overall when RIC regimens are compared with conventional conditioning regimens.
14 Therefore, we have two conflicting needs: we must deliver sufficient preparation before the transplant to control leukemia, and we must do this without exposing the patient to an excessive risk of immediate death. 15 All transplant centers have struggled to achieve this goal over the past decades, and one would like to know whether this has been achieved with different success rate in different centers.
The European Group for Blood and Marrow Transplantation (EBMT) has addressed this question in a study among 13 European centers performing the largest number of allogeneic transplants in 1st CR AML, between 1987 and 1995. 16 The study included 522 patients and leukemia-free survival was significantly different in different centers, ranging from 36 to 76%. 16 This was due exclusively to a difference in TRM, which ranged from 8 to 54%, whereas relapse rates were similar. Programs with a 54% TRM would have difficulties in showing a survival advantage over CT, whereas programs with 8% TRM would probably have superior survival of transplants when compared to the CT arm. A center effect was recently confirmed by the International Blood and Marrow Transplant Registry (IBMTR). 17 Therefore the answer is yes, mortality differs among transplant centers and reasons for this differences should probably be investigated more thoroughly. In our unit, we have used a standard conditioning regimen, cyclophosphamide and TBI, over the past two decades, for patients with AML in 1st CR under the age of 50, undergoing an allogeneic BMT. We therefore asked the question: how high is TRM and has this changed with time? To answer this question, we have analyzed 170 such patients, together with variables predicting major end points such as TRM, relapse and survival.
Patients and methods

Patients
One hundred and seventy patients with de novo AML in 1st CR received an allogeneic BMT in our unit between 1980 and 2003. The median year of transplant is 1990, and results will be presented for the two cohorts transplanted before or after 1990. Median follow-up for surviving patients is 7121 days (range 5986-9400) for patients transplanted before 1990 and 4285 days (range 785-5867) for those transplanted in or after the year 1990. The two groups had comparable white blood cells counts (WBC) and extramedullary disease on diagnosis (Table 1) . Differences between the two groups included patients' age, FAB subtype, cytogenetics, number of courses of CT to enter remission, interval from diagnosis to transplant, TBI dose and total cell dose ( Table 1) .
The distribution of the morphologic types of AML was done according to FAB classification. 18 
Conditioning regimen and GVHD prophylaxis
The conditioning regimen consisted of cyclophosphamide (120 mg/kg) and TBI for all patients: the dose of TBI was 9.9 Gy (3.3 Gy/day for 3 days) in 164 patients (96%) and 10-12 Gy in 6 patients. The dose of TBI received differed in the two groups of patients owing to correction of the dose after 1990 19 (Table 1 ). There were three groups of GVHD prophylaxis: cyclosporin (CyA) 1-2 mg/kg alone and in combination with low-dose methotrexate (MTX) (10 mg/kg on day þ 1 and 8 mg/kg on days þ 3, þ 6 and þ 11) and Cya 5 mg/kg alone. The distribution of these three groups was different between patients grafted before or after 1990 (Table 1) . GVHD was graded using standard criteria. 20, 21 Statistical analysis Patients' data were analyzed with the NCSS package. Comparisons were carried out using the w 2 test for categorical variables and the non-parametric MannWhitney test for continuous variables. End points for survival analysis were death without relapse (TRM), death due to relapse (relapse-related death, RRD) or death due to any cause. The survival curves for TRM and RRD were estimated using the cumulative incidence (CI) accounting for the fact that these end points are competing causes of death. Univariate and multivariate survival analyses were carried out using the Cox proportional hazard model. Variables tested were the following: number of courses of CT to achieve 1st CR (1 course vs more than 1 course); interval diagnosis transplant (less or more than 180 days); dose of TBI (less or more than 990 cGy); GVHD prophylaxis (low-dose CyA, high-dose CyA, CyA combined with MTX); year of transplant (before or after 1990)
Results
Patients' characteristics
As shown in Table 1 , patients grafted beyond 1990 were 7 years older (P ¼ 0.0001) as compared to patients grafted 
Engraftment and GVHD
The time to engraftment, as defined by the first of 3 days of neutrophil count above 0.5 Â 10 9 /l, was achieved in a median of 14 days (range 8-24) and 16 days (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in the group transplanted before or after 1990, respectively (P ¼ 0.001) ( Table 2) .
Acute (aGVHD) grades II-IV developed overall in 45% of patients (56 vs 35% of patients grafted before or after 1990, P ¼ 0.006) ( Table 2 ). Limited chronic GVHD (cGVHD) developed in 11 vs 31% of patients grafted before or after 1990 and extensive cGvHD in 6 vs 5% (P ¼ 0.002). We also analysed GVHD after stratifying patients according to the three major regimens of GVHD prophylaxis: low-dose CyA (1-2 mg/kg) alone or combined with MTX and high-dose CyA (5 mg/kg) alone. The rate of acute GVHD grades II-IV in these three groups was as follows: 58, 37 and 53% (P ¼ 0.0004). The incidence of chronic GVHD (limited þ extensive) in these 3 groups was 24, 34 and 13% (P ¼ 0.03).
Transplant related mortality
The overall CI of TRM was 30 vs 7% (P ¼ 0.0001) in the group transplanted before or after 1990, respectively (Table 2) (Figure 1 ). Causes of TRM in the groups transplanted before or after 1990 were as follows: acute GVHD (10 and 2 patients, respectively), chronic GVHD (3 and 2), infections (3 and 2), second tumors (2 and 0) and other causes (6 and 2). In univariate analysis, the following factors were associated with higher TRM: more than one course of CT to achieve remission, a longer interval diagnosis transplant (4180 days), a lower TBI dose (o990 cGy), GVHD prophylaxis without MTX and year of transplant before 1990 (Table 3) . In multivariate analysis, the only predictive factor of TRM remained the year of transplant (Po0.0001) ( Table 3) .
Relapse and RRD The CI of relapse in patients grafted before or after 1990 was 26 and 20% (P ¼ 0.2). The incidence of RRD was 26 and 11% (P ¼ 0.01) (Table 2) (Figure 2) . Patients who were grafted before 1990 and relapsed (n ¼ 21) were given reinduction CT and one received a second BMT: all 21 patients died of leukemia (Figure 3) . Patients who were grafted in or after 1990 and relapsed (n ¼ 18) were also given reinduction CT: this was then followed by a second BMT (n ¼ 2), by donor lymphocyte infusion (DLI) (n ¼ 5) or both (n ¼ 1); 6 patients of 18 survive between 1012 and 5574 days (median 4657 or 12 years). The actuarial survival after relapse is 0 and 31%, respectively (Figure 3) .
In univariate analysis, the following factors were associated with higher RRD: more than one course of CT to achieve remission, longer interval diagnosis transplant (4180 days), lower TBI dose (o990 cGy), GVHD prophylaxis with high-dose CyA and year of transplant before 1990. In multivariate analysis, the only predictive factor of RRD was GVHD prophylaxis with a high dose of CyA (P ¼ 0.0001) ( Table 3) .
Overall survival
The overall actuarial survival was 42 vs 79% for the group transplanted before or after 1990, respectively (Po0.0001) ( Table 2 ) (Figure 4 ). The following variables were significant negative predictors of survival in univariate analysis: more than one course of CT to achieve remission, longer interval diagnosis transplant (4180 days), lower TBI dose (o990 cGy), GVHD prophylaxis with high-dose CyA and year of transplant before 1990 (Table 3) . In multivariate analysis the interval diagnosis-transplant Days from BMT CI of transplant related mortality Year of BMT . 1990 (Table 3) .
Interval diagnosis transplant
Because there was a significant interaction between the interval diagnosis transplant and year of transplant, we looked at the effect of year of transplant in patients grafted within or beyond 180 days: When the interval diagnosis transplant was less than 6 months, survival was 50 vs 88% for patients grafted in the time period before or after 1990 (P ¼ 0.0001). When the interval diagnosis transplant was beyond 6 months, survival was 40 vs 66% in the two transplant eras (P ¼ 0.02). Therefore, patients grafted beyond 1990 did always better, but the effect was more pronounced in patients grafted within 6 months from diagnosis.
Discussion
We have shown in this study that survival of 1st CR AML undergoing an allogeneic transplant in or after1990 exceeds 75%, which is significantly better than results for patients Allogeneic transplant in 1CR AML D Vicente et al grafted before 1990: this is due to reduced TRM, but also to rescue of patients relapsing after transplant. Reduction of TRM is one of the major issues in allogeneic stem cell transplantation, especially for patients in 1st CR, for whom alternative therapies may exist. In this study we show a very significant reduction of transplant related deaths, which are currently 7% in the last 90 patients, from 30% before 1990, and we were interested to assess whether this was due to different patients or different transplant procedures. The two groups of patients grafted before and after 1990, indeed differed by several characteristics: most of these were unfavorable for patients grafted after 1990, such as older age, FAB subtype and shorter interval from diagnosis to transplant. As to the latter, a study by the European group for Blood and Marrow Transplantation (EBMT) 22 has suggested that the interval from diagnosis to transplant correlated inversely with the risk of relapse after autologous transplants: the longer the interval the lower the risk of relapse, possibly because of positive selection of patients with a better outcome. In the present study, the interval from diagnosis to transplant was 156 days for the most recent cohort of patients compared with 228 days for patients grafted before 1990. The only difference between the two groups, with a negative impact on patients grafted before 1990, was the higher number of patients requiring more than one course of CT to achieve remission. However, it should be stated that CT was less aggressive in the eighties and this may have been one of the reasons for this result. Therefore, patients grafted in the two time periods before or after 1990 are indeed different, but differences would pose a negative bias mainly for patients transplanted after 1990: one should also add that knowledge of favorable cytogenetics, and improvement of medical treatment for AML M3, has induced hematologists to propose transplantation for high-risk patients. In keeping with this statement, 36 vs 75% of patients grafted before or after 1990 had intermediate or high-risk cytogenetics, and were significantly older. Despite these negative biases, results of transplants after 1990 are superior, and the question is of course why this has occurred.
We therefore analysed transplant procedures in the two transplant eras, to test for changes: we could identify significant differences in cell dose, GVHD prophylaxis, and dose of TBI. Cell dose was abruptly increased in the early 1990s, after optimizing harvest procedures, 23 and the relevance of marrow cell dose on survival has been clearly shown by the EBMT in 1st CR AML: in that study, a rich marrow offered patients better outcome as compared to poor marrow (o2.7 Â 10 8 /kg) or peripheral blood. 24 A second difference was GVHD prophylaxis and we could identify three major regimens that were used in different proportion of patients grafted before or after 1990: cyclosporin high dose, cyclosporin low dose and cyclosporin low dose þ MTX. The risk of GVHD grades II-IV differed, as expected, according to the GVHD prophylaxis regimen, with lowest figures for the combination low-dose cyclosporin and MTX, and this correlated also with lowest TRM. The third difference in transplant protocols between the two groups of patients (before or after 1990) was the dose of TBI actually received, which was more accurately determined after 1990, as described elsewhere. 20 As a consequence, the group transplanted after 1990 received a slightly but significantly higher dose of TBI, compared to the group transplanted before 1990 (990 vs 966 cGy, P ¼ 0.0001). In univariate analysis, variables predicting TRM were the number of courses of CT to achieve remission, interval diagnosis transplant, TBI dose, GVHD prophylaxis and year of transplant. In multivariate analysis on TRM, the year of transplant emerged as the single most relevant predictor, possibly because it incorporated all of the discussed changes in protocols, from cell dose to GVHD prophylaxis.
Relapse is the second cause of failure of an allogeneic BMT. The number of relapses in patients grafted after 1990 was not significantly different as compared with patients grafted previously. However, we found a significant difference in RRD owing to the fact that a proportion of relapses were rescued with additional cell therapy in patients grafted in or after 1990. Indeed of the 21 relapses before 1990, only one received a second transplant and all the patients died; on the contrary, of the 18 relapses in patients grafted in or after 1990, 8 received cell therapy in the form of a second transplant and/or donor lymphocyte infusions, and six are surviving long term, with a median follow-up of over 10 years. In multivariate analysis, GVHD prophylaxis emerged as the single most significant predictor of RRD.
Therefore, TRM has been reduced by modification of transplant procedures including GVHD prophylaxis, cell dose and TBI, whereas relapses have been rescued more effectively by the use of cell therapy. The combination of these two approaches has led to improved survival. The relevance of time interval between diagnosis and transplant should also be noted: we found a strong negative impact of delaying transplants in this cohort of 170 AML patients, in particular beyond 1990, with survival of 88% for patients grafted within 6 months and 66% for patients grafted later. As in many other circumstances, these data suggest that allogeneic transplants for AML in 1st CR should be performed as soon as possible.
Over the past years, significant progress in BMT has relied on supportive care and management of infectious complications. According to a recent analysis done by the EBMT on 14 403 patients with early leukemia transplanted from HLA-identical siblings, between 1980 and 2001, improvement was mainly seen as a reduction of infectious deaths. No improvement was seen in the proportion of death due to GVHD or other causes and death from relapse have increased. 25 In the present study, we have seen a significant reduction in deaths from GVHD, 16% in the group transplanted before 1990 and 4% in or after 1990, and more importantly, a reduction in RRD from 26 to 11%. The number of infectious deaths was low in both groups.
In conclusion, allogeneic BMTs can provide, with optimized transplant protocols and supportive care, encouraging disease-free survival in patients with AML in 1st CR. It should continue to be considered an important approach when discussing treatment strategies, and may be proposed to patients with a suitable donor, early in the course of their disease.
